Ge Long Hui·2026-01-07 09:02Core Viewpoint - Huatai Securities maintains a positive outlook on JD Health as a leader in the online medical e-commerce sector, expecting steady revenue growth and sustainable profit margin improvement [1] Group 1: Revenue and Profit Forecast - The company anticipates a 25% year-on-year revenue growth for JD Health in 2025, reaching 72.7 billion yuan [1] - Non-IFRS operating profit is projected to be 4.11 billion yuan in 2025 [1] - Forecasts for non-IFRS net profit for 2025 to 2027 have been raised by 11.6%, 15.6%, and 22.4% respectively [1] Group 2: Strategic Focus Areas - Key areas of focus include the supply rhythm of new medical products and progress in initial cooperation [1] - The impact of weight loss drugs entering the medical insurance list on volume and price trends is under observation [1] - Developments in AI medical applications, O2O business expansion, and B2C medical insurance payment integration are also being monitored [1] Group 3: Target Price and Rating - The target price for JD Health has been increased from 68.3 HKD to 77.4 HKD [1] - The rating remains at "Buy" [1]